{"version":"1.0","provider_name":"GreyB","provider_url":"https:\/\/greyb.com","author_name":"Team GreyB","author_url":"https:\/\/greyb.com\/author\/admin\/","title":"2026 Generic Drug Launches: 3 APIs survived patent & market pressure.","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"bNgSZ4SUhx\"><a href=\"https:\/\/greyb.com\/blog\/the-three-safest-api-bets-for-2026-generic-drug-entry\/\">The Three Safest API Bets for 2026 Generic Drug Entry<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/greyb.com\/blog\/the-three-safest-api-bets-for-2026-generic-drug-entry\/embed\/#?secret=bNgSZ4SUhx\" width=\"600\" height=\"338\" title=\"&#8220;The Three Safest API Bets for 2026 Generic Drug Entry&#8221; &#8212; GreyB\" data-secret=\"bNgSZ4SUhx\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/greyb.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/greyb.com\/wp-content\/uploads\/2026\/02\/The-Three-Safest-API-Bets-for-2026-Generic-Drug-Entry-2-1024x576.png","thumbnail_width":1024,"thumbnail_height":576,"description":"Seventeen high-revenue small-molecule drugs were examined beyond simple patent expiry timelines. The review incorporated regulatory protections, competitor filings, and supply arrangements, factors that often surface late in the planning cycle and materially alter launch feasibility. Timing proved decisive. Several of them that appeared viable at first narrowed quickly when secondary protections persisted, or competitive activity [&hellip;]"}